Pay for one-time curative therapies as an annuity that stops at relapse
A single cell therapy can cost more than a house. Paying in yearly instalments, only while the patient stays well, spreads the cost and shares the risk.
Single-administration therapies with durable but uncertain benefit strain annual budgets and shift all risk of relapse to the payer. Annuity or performance-linked instalment models have been implemented for gene therapies for rare diseases in the US and Europe (for example for spinal muscular atrophy and haemophilia), with payments contingent on continued response. The proposal is to make annuity contracts standard for oncology cell therapies with curative intent: a fixed payment at infusion covering manufacturing, then annual payments for up to five years while the patient remains in remission, adjudicated through the treatment registry.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
Pages like this
not linked directly; found by shared links- IdeaPublic payers cover academic CAR-T at cost as a benchmark for commercial prices
Shares Prices and value, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaA neutral slot exchange so unused CAR-T manufacturing slots go to the next patient
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaPublic reference standards and potency assays for CAR-T so every lab measures alike
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaTwo-day CAR-T manufacture paired with rapid release tests that regulators accept
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaAn open interoperability standard for closed automated cell-processing machines
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaCollect and freeze T cells at diagnosis for high-risk patients, before chemotherapy
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaMutual recognition of GMP inspections for cell, gene and radiopharmaceutical plants
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaComparability by design: a digital twin and sentinel panel for cell process changes
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.